Microtubule-targeting agents in angiogenesis: where do we stand?
Angiogenesis is a key event of tumor progression and metastasis and hence a target for cancer chemotherapy. Therapeutic strategies focused on angiogenesis include the discovery of new, targeted anti-angiogenic agents and the re-evaluation of conventional anti-cancer drugs. Here, we review the most recent studies investigating the molecular and cellular mechanisms responsible for the anti-angiogenic activity of microtubule-targeting agents (MTAs). These agents include some of the most widely used and effective antitumor drugs that are also among the most anti-angiogenic. In addition, we summarize the latest results of pre-clinical and clinical studies involving MTAs administered at low metronomic doses and in anti-angiogenic combination strategies. Finally, we discuss the future development of these agents, their clinical potential and their limitations.
Pasquier
Eddy
E
FRE-CNRS 2737, CISMET (Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral), Université de la Méditerranée, 27 boulevard Jean Moulin, 13005 Marseille, France.
Honoré
Stéphane
S
Braguer
Diane
D
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D004334:Drug Administration Schedule; D006801:Humans; D009111:Local Government; D008870:Microtubules / Q000187:drug effects*; D008954:Models, Biological; D008967:Molecular Biology / Q000639:trends; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D014748:Vinca Alkaloids / Q000494:pharmacology / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D014748:Vinca Alkaloids